(ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945.
The company said the trial is primarily designed to study the safety and tolerability profile of AMP945. It will also study a number of pharmaceutical parameters and includes multiple cohorts of healthy volunteers who have received either single or multiple doses of AMP945.
“All doses have now been administered and there have been no tolerability concerns or dose-limiting adverse events,” said the company, adding analysis of the trial results will be conducted during the current quarter.
“It is exciting to have completed the dosing period of this trial and to see such a robust safety and tolerability profile for AMP945. We now plan to commence Phase 2 clinical trials in patients within the next 12 months.” said Dr John Lambert, CEO of Amplia. “I would also like to take this opportunity to thank everyone who has been involved in this trial and, in particular, to the volunteers who agreed to participate.”